Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3372689
Overview
- Phase
- Phase 1
- Intervention
- LY3372689
- Conditions
- Healthy
- Sponsor
- Eli Lilly and Company
- Enrollment
- 54
- Locations
- 1
- Primary Endpoint
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Observed by the Investigator During Study Drug Administration
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3372689 or placebo and will remain in the study for up to eight weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Overtly healthy vasectomized male or a female who cannot get pregnant
- •Have a body mass index (BMI) of 18.5 to ≤30 kilograms per square meter (kg/m²)
- •Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
- •Have veins suitable for ease of blood sampling
Exclusion Criteria
- •Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
- •Have previously participated or withdrawn from this study
- •Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking for study procedure
- •Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate or could interfere with understanding the results of the study
Arms & Interventions
LY3372689
LY3372689 administered orally
Intervention: LY3372689
Placebo
Placebo administered orally
Intervention: Placebo
Outcomes
Primary Outcomes
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Observed by the Investigator During Study Drug Administration
Time Frame: Baseline through final follow-up at approximately Day 30
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Secondary Outcomes
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3372689(Day 1 postdose through Day 15)
- PK: Area Under the Concentration Versus Time Curve (AUC) of LY3372689(Day 1 postdose through Day 15)